Medtronic (MDT) Stock Forecast & Price Target
Medtronic (MDT) Analyst Ratings
Bulls say
Medtronic's strong performance in the neuromodulation and diabetes sectors, highlighted by a 240 basis point increase in market share and mid-single-digit revenue growth, indicates robust demand and successful product adoption, particularly with the MiniMed 780G AID system. The company's positive revenue outlook for FY25, estimated to rise by 3.4-3.8%, along with an EPS guidance reflecting a 10-11% annual growth rate (excluding currency effects), showcases its financial health and capacity for profitability. Additionally, improvements in non-GAAP gross and operating margins, driven partly by favorable currency effects, complement Medtronic's potential for enhanced market share in the cardiac ablation space, further supporting a bullish outlook on its stock.
Bears say
Medtronic's stock outlook is negatively affected by anticipated revenue growth slowing to low-single digits due to unsuccessful new product launches and market share losses in certain categories, alongside flat or declining operating margins that could result in below-consensus earnings. Additionally, the company faces risks from competitive product introductions, disappointing sales from promising new technologies, and a projected 5% unfavorable impact from foreign exchange on earnings per share in FY25. The recent decline in organic growth, which fell to 4.1% in the most recent quarter, further underscores the challenges posed by distributor destocking negatively impacting the Medical Surgical segment.
This aggregate rating is based on analysts' research of Medtronic and is not a guaranteed prediction by Public.com or investment advice.
Medtronic (MDT) Analyst Forecast & Price Prediction
Start investing in Medtronic (MDT)
Order type
Buy in
Order amount
Est. shares
0 shares